- Home
- MBLY vs MRNA Comparison
MBLY vs MRNA Comparison
Compare MBLY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBLY
- MRNA
- Stock Information
- Founded
- MBLY 1999
- MRNA 2010
- Country
- MBLY Israel
- MRNA United States
- Employees
- MBLY N/A
- MRNA N/A
- Industry
- MBLY Computer Software: Prepackaged Software
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBLY Technology
- MRNA Health Care
- Exchange
- MBLY Nasdaq
- MRNA Nasdaq
- Market Cap
- MBLY 17.6B
- MRNA 16.0B
- IPO Year
- MBLY 2022
- MRNA 2018
- Fundamental
- Price
- MBLY $16.02
- MRNA $34.06
- Analyst Decision
- MBLY Buy
- MRNA Hold
- Analyst Count
- MBLY 21
- MRNA 20
- Target Price
- MBLY $23.79
- MRNA $76.35
- AVG Volume (30 Days)
- MBLY 7.9M
- MRNA 10.7M
- Earning Date
- MBLY 01-30-2025
- MRNA 02-20-2025
- Dividend Yield
- MBLY N/A
- MRNA N/A
- EPS Growth
- MBLY N/A
- MRNA N/A
- EPS
- MBLY N/A
- MRNA N/A
- Revenue
- MBLY $1,801,000,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- MBLY N/A
- MRNA N/A
- Revenue Next Year
- MBLY $18.75
- MRNA N/A
- P/E Ratio
- MBLY N/A
- MRNA N/A
- Revenue Growth
- MBLY N/A
- MRNA N/A
- 52 Week Low
- MBLY $10.48
- MRNA $31.94
- 52 Week High
- MBLY $34.00
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- MBLY 40.65
- MRNA 34.88
- Support Level
- MBLY $14.92
- MRNA $33.34
- Resistance Level
- MBLY $17.67
- MRNA $35.68
- Average True Range (ATR)
- MBLY 1.42
- MRNA 2.46
- MACD
- MBLY -0.48
- MRNA -0.75
- Stochastic Oscillator
- MBLY 14.49
- MRNA 12.49
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. Mobileye is the Company's only reportable operating segment. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It also provides data services to Expedite Maintenance Operations with AI-Powered Road Survey Technology.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.